Companies
Morrison Foerster
represented a party in the 2026 $2.25 billion global patent settlement between Moderna and Arbutus/Genevant over mRNA lipid-nanoparticle delivery technology, confirmed via the firm's own news page and independent legal-press coverage of the settlement — a genuine, high-value, on-topic biotech patent dispute resolution.
- Country
- United States
Biotech patent litigation
Coverage
| US | |
|---|---|
| regulatory-legal | ✓ |
Regulatorsfda
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Bio-arbitration | regulatory-legal | High | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.